Proqr Therapeutics Bv Stock Buy Hold or Sell Recommendation
| PRQR Stock | USD 1.69 0.05 2.87% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding ProQR Therapeutics BV is 'Strong Sell'. A buy or sell recommendation provided by Macroaxis is an automated analysis based on historical performance and your stated risk tolerance. It serves as guidance on whether to purchase or sell ProQR Therapeutics BV within the specified time frame.
Check out ProQR Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as ProQR and provide practical buy, sell, or hold advice based on investors' constraints. ProQR Therapeutics BV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index.
ProQR |
Execute ProQR Therapeutics Buy or Sell Advice
The ProQR recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on ProQR Therapeutics BV. Macroaxis does not own or have any residual interests in ProQR Therapeutics BV or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute ProQR Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
ProQR Therapeutics Trading Alerts and Improvement Suggestions
| ProQR Therapeutics generated a negative expected return over the last 90 days | |
| ProQR Therapeutics may become a speculative penny stock | |
| ProQR Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 18.91 M. Net Loss for the year was (27.76 M) with profit before overhead, payroll, taxes, and interest of 19.55 M. | |
| ProQR Therapeutics BV currently holds about 156.4 M in cash with (36.39 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.19, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| ProQR Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 14.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: ProQR Therapeutics Full Year 2024 Earnings Misses Expectations |
ProQR Therapeutics current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. ProQR analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. ProQR analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Average Consensus Strong Buy
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
ProQR Therapeutics Returns Distribution Density
The distribution of ProQR Therapeutics' historical returns is an attempt to chart the uncertainty of ProQR Therapeutics' future price movements. The chart of the probability distribution of ProQR Therapeutics daily returns describes the distribution of returns around its average expected value. We use ProQR Therapeutics BV price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of ProQR Therapeutics returns is essential to provide solid investment advice for ProQR Therapeutics.
| Mean Return | -0.99 | Value At Risk | -8.58 | Potential Upside | 6.61 | Standard Deviation | 5.21 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of ProQR Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
ProQR Stock Institutional Investors
The ProQR Therapeutics' institutional investors refer to entities that pool money to purchase ProQR Therapeutics' securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | Point72 Asset Management, L.p. | 2024-12-31 | 1.5 M | Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-12-31 | 1.2 M | M28 Capital Management Lp | 2024-12-31 | 1 M | Ghost Tree Capital, Llc | 2024-09-30 | 887.7 K | Macquarie Group Ltd | 2024-12-31 | 620 K | Altium Capital Management, Lp | 2024-12-31 | 575 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 486 K | Walleye Trading Advisors, Llc | 2024-12-31 | 451.3 K | Northern Trust Corp | 2024-12-31 | 417.4 K | Adage Capital Partners Gp Llc | 2024-12-31 | 9.6 M | Privium Fund Management B.v. | 2024-12-31 | 5 M |
ProQR Therapeutics Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Capital Expenditures | 924K | 484K | 708K | 1.4M | 1.4M | 943.5K | |
| End Period Cash Flow | 75.8M | 187.5M | 94.8M | 118.9M | 149.4M | 98.4M | |
| Change In Cash | (36.1M) | 111.7M | (92.7M) | 24.2M | 30.5M | 32.0M | |
| Net Borrowings | 1.5M | 13.8M | 26.8M | (45.0M) | (40.5M) | (38.5M) | |
| Free Cash Flow | (48.0M) | (26.5M) | (69.2M) | 20.2M | (37.8M) | (39.7M) | |
| Depreciation | 2.4M | 2.3M | 2.5M | 2.5M | 2.8M | 1.7M | |
| Other Non Cash Items | (5.8M) | 2.0M | (3.7M) | (5.4M) | (474K) | (497.7K) | |
| Net Income | (46.6M) | (61.7M) | (64.9M) | (27.5M) | (27.8M) | (29.2M) | |
| Change To Netincome | 8.8M | 2.3M | 8.3M | (484K) | (556.6K) | (528.8K) | |
| Investments | (924K) | (425K) | (702K) | 4.3M | (4.1M) | (3.9M) |
ProQR Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to ProQR Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that ProQR Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a ProQR stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.98 | |
β | Beta against Dow Jones | 0.18 | |
σ | Overall volatility | 4.86 | |
Ir | Information ratio | -0.17 |
ProQR Therapeutics Volatility Alert
ProQR Therapeutics BV exhibits very low volatility with skewness of 0.48 and kurtosis of 2.95. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure ProQR Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact ProQR Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.ProQR Therapeutics Fundamentals Vs Peers
Comparing ProQR Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze ProQR Therapeutics' direct or indirect competition across all of the common fundamentals between ProQR Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as ProQR Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of ProQR Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing ProQR Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare ProQR Therapeutics to competition |
| Fundamentals | ProQR Therapeutics | Peer Average |
| Return On Equity | -0.43 | -0.31 |
| Return On Asset | -0.12 | -0.14 |
| Profit Margin | (1.42) % | (1.27) % |
| Operating Margin | (2.27) % | (5.51) % |
| Current Valuation | 35.09 M | 16.62 B |
| Shares Outstanding | 105.91 M | 571.82 M |
| Shares Owned By Insiders | 14.49 % | 10.09 % |
| Shares Owned By Institutions | 53.53 % | 39.21 % |
| Number Of Shares Shorted | 965.86 K | 4.71 M |
| Price To Earning | (1.97) X | 28.72 X |
| Price To Book | 1.86 X | 9.51 X |
| Price To Sales | 9.16 X | 11.42 X |
| Revenue | 18.91 M | 9.43 B |
| Gross Profit | 19.55 M | 27.38 B |
| EBITDA | (24.12 M) | 3.9 B |
| Net Income | (27.76 M) | 570.98 M |
| Cash And Equivalents | 156.4 M | 2.7 B |
| Cash Per Share | 2.19 X | 5.01 X |
| Total Debt | 17.22 M | 5.32 B |
| Debt To Equity | 0.70 % | 48.70 % |
| Current Ratio | 5.93 X | 2.16 X |
| Book Value Per Share | 0.89 X | 1.93 K |
| Cash Flow From Operations | (36.39 M) | 971.22 M |
| Short Ratio | 3.22 X | 4.00 X |
| Earnings Per Share | (0.35) X | 3.12 X |
| Target Price | 9.71 | |
| Beta | 0.24 | -0.15 |
| Market Capitalization | 178.98 M | 19.03 B |
| Total Asset | 167.96 M | 29.47 B |
| Retained Earnings | (427.16 M) | 9.33 B |
| Working Capital | 114.94 M | 1.48 B |
| Current Asset | 97.77 M | 9.34 B |
| Current Liabilities | 5.49 M | 7.9 B |
ProQR Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as ProQR . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About ProQR Therapeutics Buy or Sell Advice
When is the right time to buy or sell ProQR Therapeutics BV? Buying financial instruments such as ProQR Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having ProQR Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Hybrid Mix Funds Thematic Idea Now
Hybrid Mix Funds
Funds or Etfs that are made of portfolios of stocks, bonds, or cash instruments with different maturity horizons and characteristics. The Hybrid Mix Funds theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Hybrid Mix Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for ProQR Stock Analysis
When running ProQR Therapeutics' price analysis, check to measure ProQR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProQR Therapeutics is operating at the current time. Most of ProQR Therapeutics' value examination focuses on studying past and present price action to predict the probability of ProQR Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProQR Therapeutics' price. Additionally, you may evaluate how the addition of ProQR Therapeutics to your portfolios can decrease your overall portfolio volatility.